SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., President and CEO of SCYNEXIS, will engage in a fireside chat on Thursday, October 17, at 11:30 A.M. ET.
The event will be held virtually, and interested parties can sign up to view the presentation through a provided link. Additionally, one-on-one investor meetings will be available after the event upon request, which can be arranged through a separate link or by contacting a Maxim representative.
SCYNEXIS (NASDAQ: SCYX), un'azienda biotecnologica focalizzata sullo sviluppo di medicine innovative per infezioni difficili da trattare e resistenti ai farmaci, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., Presidente e CEO di SCYNEXIS, prenderà parte a una chiacchierata informale il giovedì 17 ottobre, alle 11:30 A.M. ET.
L'evento si terrà in modalità virtuale e le parti interessate possono registrarsi per visualizzare la presentazione tramite un link fornito. Inoltre, saranno disponibili incontri individuali con gli investitori dopo l'evento su richiesta, che possono essere organizzati tramite un link separato o contattando un rappresentante di Maxim.
SCYNEXIS (NASDAQ: SCYX), una empresa biotecnológica centrada en desarrollar medicamentos innovadores para infecciones difíciles de tratar y resistentes a los fármacos, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., Presidente y CEO de SCYNEXIS, participará en una charla informal el jueves 17 de octubre, a las 11:30 A.M. ET.
El evento se llevará a cabo de forma virtual, y las partes interesadas pueden registrarse para ver la presentación a través de un enlace proporcionado. Además, se ofrecerán reuniones individuales con inversores después del evento a solicitud, que pueden ser organizadas a través de un enlace separado o contactando a un representante de Maxim.
SCYNEXIS (NASDAQ: SCYX), 치료가 어렵고 약물 내성이 있는 감염 치료를 위한 혁신적인 약물을 개발하는 데 집중하는 생명공학 회사는 2024 Maxim Healthcare Virtual Summit에 참가한다고 발표했습니다. David Angulo, M.D., SCYNEXIS의 회장이자 CEO가 10월 17일 목요일 오전 11시 30분 ET에 화상 대담에 참여하게 됩니다.
이 행사는 가상으로 진행되며, 관심 있는 사람들은 제공된 링크를 통해 발표를 시청하기 위해 등록할 수 있습니다. 또한, 행사가 끝난 후 개별 투자자 미팅이 요청에 따라 이용 가능하며, 별도의 링크를 통해 또는 Maxim 대표에게 연락하여 조정할 수 있습니다.
SCYNEXIS (NASDAQ: SCYX), une société de biotechnologie axée sur le développement de médicaments innovants pour les infections difficiles à traiter et résistantes aux médicaments, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., Président et CEO de SCYNEXIS, participera à une discussion informelle le jeudi 17 octobre, à 11h30 ET.
L'événement se tiendra virtuellement, et les parties intéressées peuvent s'inscrire pour visionner la présentation via un lien fourni. De plus, des réunions individuelles avec les investisseurs seront disponibles après l'événement sur demande, pouvant être organisées via un lien séparé ou en contactant un représentant de Maxim.
SCYNEXIS (NASDAQ: SCYX), ein biotechnologisches Unternehmen, das sich auf die Entwicklung innovativer Medikamente für schwer zu behandelnde und arzneimittelresistente Infektionen spezialisiert hat, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit angekündigt. David Angulo, M.D., Präsident und CEO von SCYNEXIS, wird am Donnerstag, den 17. Oktober, um 11:30 Uhr ET an einem informellen Gespräch teilnehmen.
Die Veranstaltung findet virtuell statt, und interessierte Parteien können sich über den bereitgestellten Link für die Präsentation anmelden. Darüber hinaus werden eins-zu-eins-Investorenmeetings nach der Veranstaltung auf Anfrage verfügbar sein, die über einen separaten Link oder durch Kontaktaufnahme mit einem Vertreter von Maxim organisiert werden können.
- None.
- None.
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET.
| Maxim Healthcare Virtual Summit Details: | |
| Format: | Fireside chat |
| Date: | Thursday, October 17, 2024 |
| Time: | 11:30 A.M. ET |
| Location: | Virtual |
To sign up to view the presentation, click here.
1x1 investor meetings will be available after the event upon request through the following link or by contacting your Maxim representative.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
FAQ
When is SCYNEXIS (SCYX) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent SCYNEXIS (SCYX) at the 2024 Maxim Healthcare Virtual Summit?
What is the format of SCYNEXIS's (SCYX) presentation at the 2024 Maxim Healthcare Virtual Summit?
How can investors view SCYNEXIS's (SCYX) presentation at the 2024 Maxim Healthcare Virtual Summit?
Are one-on-one meetings available with SCYNEXIS (SCYX) management after the 2024 Maxim Healthcare Virtual Summit?
